Orange Book patents could face more challenges after appellate ruling
Court of Appeals for the First Circuit finds that Sanofi-Aventis improperly listed a patent for an “integral component” of a drug product and may be liable to antitrust claims
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.